{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:29:35Z","timestamp":1791872975621,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted disruption of leukocyte trafficking to the gut represents a promising approach for the treatment of inflammatory bowel diseases (IBDs). CCR5, the shared receptor for MIP1\u03b1 and \u03b2 and RANTES, is expressed by multiple leukocytes. Here, we aimed to determine the role of CCR5 in mediating leukocyte trafficking in models of colitis and evaluate the therapeutic potential of maraviroc, an orally active CCR5 antagonist used in the treatment of CCR5-tropic HIV. Acute and chronic colitis were induced by administration of DSS or TNBS to wild-type and CCR5<jats:sup>\u2212\/\u2212<\/jats:sup> mice or adoptive transfer of splenic na\u00efve CD4<jats:sup>+<\/jats:sup> T-cells from wild type or CCR5<jats:sup>\u2212\/\u2212<\/jats:sup> mice into RAG-1<jats:sup>\u2212\/\u2212<\/jats:sup>. CCR5 gene ablation reduced the mucosal recruitment and activation of CCR5-bearing CD4<jats:sup>+<\/jats:sup> and CD11b<jats:sup>+<\/jats:sup> leukocytes, resulting in profound attenuation of signs and symptoms of inflammation in the TNBS and transfer models of colitis. In the DSS\/TNBS colitis and in the transfer model, maraviroc attenuated development of intestinal inflammation by selectively reducing the recruitment of CCR5 bearing leukocytes. In summary, CCR5 regulates recruitment of blood leukocytes into the colon indicating that targeting CCR5 may offer therapeutic options in IBDs.<\/jats:p>","DOI":"10.1038\/srep30802","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T10:04:53Z","timestamp":1470391493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis"],"prefix":"10.1038","volume":"6","author":[{"given":"Andrea","family":"Mencarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"BFsrep30802_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","volume":"147","author":"S Danese","year":"2014","unstructured":"Danese, S. & Pan\u00e9s, J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 147, 981\u2013989 (2014).","journal-title":"Gastroenterology."},{"key":"BFsrep30802_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","volume":"147C","author":"I Mitroulis","year":"2015","unstructured":"Mitroulis, I. et al. Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 147C, 123\u2013135 (2015).","journal-title":"Pharmacol Ther."},{"key":"BFsrep30802_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ibd.20480","volume":"14","author":"NP Zimmerman","year":"2008","unstructured":"Zimmerman, N. P., Vongsa, R. A., Wendt, M. K. & Dwinell, M. B. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 14, 1000\u20131011 (2008).","journal-title":"Inflamm Bowel Dis."},{"key":"BFsrep30802_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 32, 659\u2013702 (2014).","journal-title":"Annu Rev Immunol."},{"key":"BFsrep30802_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","volume":"16","author":"M Oppermann","year":"2004","unstructured":"Oppermann, M. Chemokine receptor CCR5: insights into structure, function and regulation. Cellular Signalling 16, 1201\u20131210 (2004).","journal-title":"Cellular Signalling"},{"key":"BFsrep30802_CR6","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.4049\/jimmunol.164.12.6303","volume":"164","author":"PG Andres","year":"2000","unstructured":"Andres, P. G. et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol. 164, 6303\u20136312 (2000).","journal-title":"J Immunol."},{"key":"BFsrep30802_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1462-5822.2012.01812.x","volume":"14","author":"PJ Klasse","year":"2012","unstructured":"Klasse, P. J. The molecular basis of HIV entry. Cell Microbiol. 14, 1183\u20131192 (2012).","journal-title":"Cell Microbiol."},{"key":"BFsrep30802_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 370, 901\u2013910 (2014).","journal-title":"N Engl J Med."},{"key":"BFsrep30802_CR9","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/j.ddtec.2012.07.011","volume":"10","author":"B Lagane","year":"2013","unstructured":"Lagane, B., Garcia-Perez, J. & Kellenberger, E. Modeling the allosteric modulation of CCR5 function by Maraviroc. Drug Discov Today Technol. 10, e297\u2013e305 (2013).","journal-title":"Drug Discov Today Technol."},{"key":"BFsrep30802_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.1241475","volume":"341","author":"Q Tan","year":"2013","unstructured":"Tan, Q. et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341, 1387\u20131390 (2013).","journal-title":"Science"},{"key":"BFsrep30802_CR11","doi-asserted-by":"publisher","first-page":"33409","DOI":"10.1074\/jbc.M111.279596","volume":"286","author":"J Garcia-Perez","year":"2011","unstructured":"Garcia-Perez, J. et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem. 286, 33409\u201333421 (2011).","journal-title":"J Biol Chem."},{"key":"BFsrep30802_CR12","first-page":"225","volume":"37","author":"A Ermocida","year":"2014","unstructured":"Ermocida, A. et al. Extravirologic modulation of immune response by an NRTI-sparingantiretroviral regimen including darunavir and maraviroc. New Microbiol. 37, 225\u2013229 (2014).","journal-title":"New Microbiol."},{"key":"BFsrep30802_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jac\/dks432","volume":"68","author":"H Arberas","year":"2013","unstructured":"Arberas, H. et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. Antimicrob Chemother. 68, 577\u2013586 (2013).","journal-title":"Antimicrob Chemother."},{"key":"BFsrep30802_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1201248","volume":"367","author":"R Reshef","year":"2012","unstructured":"Reshef, R. et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 367, 135\u2013145 (2012).","journal-title":"N Engl J Med."},{"key":"BFsrep30802_CR15","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.113.001278","volume":"127","author":"S Cipriani","year":"2013","unstructured":"Cipriani, S. et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 127, 2114\u20132124 (2013).","journal-title":"Circulation"},{"key":"BFsrep30802_CR16","doi-asserted-by":"publisher","first-page":"15770","DOI":"10.1073\/pnas.232583599","volume":"99","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci, S. et al. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci USA 99, 15770\u201315775 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep30802_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1074-7613(02)00476-4","volume":"17","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci, S. et al. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity 17, 769\u2013780 (2002).","journal-title":"Immunity"},{"key":"BFsrep30802_CR18","doi-asserted-by":"publisher","first-page":"G135","DOI":"10.1152\/ajpgi.90462.2008","volume":"296","author":"DV Ostanin","year":"2009","unstructured":"Ostanin, D. V. et al. T cell transfer model of chronic colitis: concepts, considerations and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 296, G135\u2013G146 (2009).","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"BFsrep30802_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12192","volume":"260","author":"CC Bain","year":"2014","unstructured":"Bain, C. C. & Mowat, A. M. Macrophages in intestinal homeostasis and inflammation. Immunol Rev. 260, 102\u2013117 (2014).","journal-title":"Immunol Rev."},{"key":"BFsrep30802_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/mi.2014.40","volume":"8","author":"V Cerovic","year":"2015","unstructured":"Cerovic, V. et al. Lymph-borne CD8\u03b1+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells. Mucosal Immunol. 8, 38\u201348 (2015).","journal-title":"Mucosal Immunol."},{"key":"BFsrep30802_CR21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/eji.1830270916","volume":"27","author":"W Tietz","year":"1997","unstructured":"Tietz, W. & Hamann, A. The migratory behavior of murine CD4+ cells of memory phenotype. Eur J Immunol. 27, 2225\u20132232 (1997).","journal-title":"Eur J Immunol."},{"key":"BFsrep30802_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1073\/pnas.94.5.1925","volume":"94","author":"CC Bleul","year":"1997","unstructured":"Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94, 1925\u20131930 (1997).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep30802_CR23","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1172\/JCI77837","volume":"124","author":"CR Mackay","year":"2014","unstructured":"Mackay, C. R. Cxcr3(+)ccr5(+) t cells and autoimmune diseases: guilty as charged? J clin invest 124, 3682\u20133684 (2014).","journal-title":"J clin invest"},{"key":"BFsrep30802_CR24","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/ni.2967","volume":"15","author":"CC Bain","year":"2014","unstructured":"Bain, C. C. et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol. 15, 929\u2013937 (2014).","journal-title":"Nat Immunol."},{"key":"BFsrep30802_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mi.2012.89","volume":"6","author":"CC Bain","year":"2013","unstructured":"Bain, C. C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498\u2013510 (2013).","journal-title":"Mucosal Immunol."},{"key":"BFsrep30802_CR26","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.immuni.2012.08.026","volume":"37","author":"E Zigmond","year":"2012","unstructured":"Zigmond, E. et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37, 1076\u20131090 (2012).","journal-title":"Immunity"},{"key":"BFsrep30802_CR27","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/eji.201040965","volume":"41","author":"B Weber","year":"2011","unstructured":"Weber, B., Saurer, L., Schenk, M., Dickgreber, N. & Mueller, C. CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions. Eur J Immunol. 41, 773\u2013779 (2011).","journal-title":"Eur J Immunol."},{"key":"BFsrep30802_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/84205","volume":"2","author":"SA Luther","year":"2001","unstructured":"Luther, S. A. & Cyster, J. G. Chemokines as regulators of T cell differentiation. Nat Immunol. 2, 102\u2013107 (2001).","journal-title":"Nat Immunol."},{"key":"BFsrep30802_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","volume":"474","author":"KJ Maloy","year":"2011","unstructured":"Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298\u2013306 (2011).","journal-title":"Nature"},{"key":"BFsrep30802_CR30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.immuni.2012.08.026","volume":"37","author":"E Zigmond","year":"2012","unstructured":"Zigmond, E. et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37, 1076\u20131090 (2012).","journal-title":"Immunity"},{"key":"BFsrep30802_CR31","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.4049\/jimmunol.0903987","volume":"184","author":"AM Platt","year":"2010","unstructured":"Platt, A. M., Bain, C. C., Bordon, Y., Sester, D. P. & Mowat, A. M. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J Immunol. 184, 6843\u20136854 (2010).","journal-title":"J Immunol."},{"key":"BFsrep30802_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0016-5085(97)70030-1","volume":"112","author":"J Rugtveit","year":"1997","unstructured":"Rugtveit, J. et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112, 1493\u20131505 (1997).","journal-title":"Gastroenterology"},{"key":"BFsrep30802_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s004390100462","volume":"108","author":"A Rector","year":"2001","unstructured":"Rector, A. et al. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet. 108, 190\u2013193 (2001).","journal-title":"Hum Genet."},{"key":"BFsrep30802_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.MIB.0000209790.21737.28","volume":"12","author":"L Henckaerts","year":"2006","unstructured":"Henckaerts, L. et al. CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis. Inflamm Bowel Dis. 12, 272\u2013277 (2006).","journal-title":"Inflamm Bowel Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep30802","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T21:35:58Z","timestamp":1672868158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep30802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,14]]}},"alternative-id":["BFsrep30802"],"URL":"https:\/\/doi.org\/10.1038\/srep30802","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"assertion":[{"value":"16 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30802"}}